Physician profile
David Schull
NPI 1750300356
$939.71
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $100 · 2021: $188 · 2022: $16.96 · 2023: $116 · 2024: $98.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $196.12 | 2019-2024 | Adstiladrin |
| Astellas Pharma US INC | $172.33 | 2019-2021 | |
| Pfizer INC. | $124.69 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $100.09 | 2023 | Pylarify |
| Endo Pharmaceuticals INC. | $96.05 | 2019-2020 | |
| Boston Scientific Corporation | $65.06 | 2020-2021 | |
| Tolmar Pharmaceuticals, INC. | $47.58 | 2019-2021 | |
| Coloplast Corp | $32.52 | 2022-2023 | Speedicath |
| Allergan, INC. | $24.47 | 2020-2021 | |
| Urogen Pharma, INC. | $20.10 | 2021 | |
| Clarus Therapeutics INC. | $16.71 | 2021 | |
| C. R. Bard Foundation, INC. | $16.54 | 2019 | |
| Janssen Biotech, INC. | $14.37 | 2019 | |
| Antares Pharma, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.